Long-term Management of Panuveitis and Choroidal Mass Associated with Rosai Dorfman Disease with Pegylated Interferon

Ocul Immunol Inflamm. 2022 Jul;30(5):1078-1082. doi: 10.1080/09273948.2020.1867190. Epub 2021 Mar 8.

Abstract

Purpose: To present a patient with Rosai-Dorfman Disease (RDD), a histiocytic proliferative disorder typified by lymphadenopathy with rare ocular manifestations, who developed panuveitis that responded to pegylated interferon.

Methods: Descriptive case report of a patient with RDD with multi-organ involvement including ocular manifestations including bilateral panuveitis with choroidal masses.

Results: A 54-year-old African American woman with known systemic RDD of the breast, lung, and gastrointestinal tract presented with panuveitis with choroidal masses in both eyes. Her systemic and ocular disease initially responded well to oral and topical steroid therapy. Later, however, her systemic disease progressed with multiple muscular and bony lesions. Systemic therapy was switched to pegylated interferon, a cytokine with antiviral, antitumor and immunomodulatory activity. After 14 months of therapy with pegylated interferon, the patient's systemic and ocular disease stabilized.

Conclusion: Rosai-Dorfman disease may be complicated by panuveitis and choroidal masses that may respond to pegylated interferon with stabilization of systemic and ocular manifestations. A multi-disciplinary approach is essential given the unique diagnostic and management challenges of RDD.

Keywords: Rosai-Dorfman disease; histiocytes; choroidal mass; panuveitis; pegylated interferon.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use
  • Female
  • Histiocytosis, Sinus* / complications
  • Histiocytosis, Sinus* / diagnosis
  • Histiocytosis, Sinus* / drug therapy
  • Humans
  • Interferons
  • Middle Aged
  • Panuveitis* / complications
  • Panuveitis* / diagnosis
  • Panuveitis* / drug therapy
  • Polyethylene Glycols / therapeutic use
  • Steroids

Substances

  • Antiviral Agents
  • Steroids
  • Polyethylene Glycols
  • Interferons